Acquisition Announced Sponsor buyer
Zydus Worldwide DMCC acquisition of Assertio Holdings
US$166m consideration
Announced 8 Apr 2026 · NASDAQ: ASRT · US$23.50 cash per share · 35% premium
Advisers
Assertio Holdings
Target
- Financial adviser
- Legal adviser
- Communications
- Target
- Assertio Holdings
- Acquirer
- Zydus Worldwide DMCC
- Sponsor
- Garda Therapeutics
- Target based in
- United States
- Buyer based in
- United Arab Emirates (unverified)
- Sector
- Pharma
In the league tables
Similar deals
- SERB Pharmaceuticals acquisition of Exclusive development and commercialisation rights to Idefirix in Europe and MENA May 2026 · US$134m · Pharma
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Royalty Pharma acquisition of PTC Therapeutics' remaining royalty on Roche's Evrysdi Jan 2026 · US$240m · Specialty finance and leasing
- Aurobindo acquisition of Lannett Jul 2026 · US$250m · Pharma
- AnaptysBio outstanding common stock share buy-back Mar 2026 · US$100m · Biotech
Sources
- 9 Apr 2026 Tender offer communication (SC TO-C), Assertio Holdings, Inc. sec.gov
- 9 Apr 2026 Target tender offer communication (SC14D9C), Assertio Holdings, Inc. sec.gov
- 9 Apr 2026 Press release (EX-99.1, exhibit), Assertio Announces Agreement to be Acquired sec.gov
- 9 Apr 2026 Gibson Dunn Advises Assertio Holdings on Sale of the Company and Its U.S. Sales and Distribution Rights for Seven Branded Products gibsondunn.com
- 13 May 2026 Press release (EX-99.1, exhibit), Assertio to Be Acquired by Zydus Worldwide DMCC sec.gov
- 13 May 2026 Zydus to Acquire Assertio paulweiss.com
- 14 May 2026 Gibson Dunn Advises Assertio on Sale to Zydus Worldwide DMCC gibsondunn.com
- 18 May 2026 Tender offer statement (SC TO-T), Assertio Holdings, Inc. sec.gov
- 18 May 2026 Target response to tender offer (SC 14D9), Assertio Holdings, Inc. sec.gov


